China Interventional Cardiovascular Device Industry Report,2014-2017
  • Sep.2014
  • Hard Copy
  • USD $2,400
  • Pages:112
  • Single User License
    (PDF Unprintable)       
  • USD $2,200
  • Code: ZLC009
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $3,500
  • Hard Copy + Single User License
  • USD $2,600

The prevalence of cardiovascular disease in China impacted by accelerated aging of population and changes in consumption concept, dietary habit, way of working and other lifestyles has been growing year after year, thereby promoting the development of domestic percutaneous coronary intervention (PCI) market. PCI cases in China totaled 454,505 in 2013, up 16.9% from a year earlier; meanwhile the interventional cardiovascular device industry there was worth RMB20.12 billion.

At present, half of the Chinese interventional cardiovascular device industry is dominated by domestic companies led by MicroPort, Lepu Medical, Lifetech Scientific, and Dalian Yinyi. In 2013, 53.4% of the Chinese market was controlled by domestic companies, 31.2% by foreign counterparts represented by Johnson & Johnson, Medtronic, Boston Scientific, Abbott, B. Braun and Terumo, and 15.4% by those invested by Hong Kong, Macao and Taiwan.

Interventional cardiovascular devices in China include cardiovascular stent, catheter, guidewire, balloon, surgical auxiliary devices, etc., among which cardiovascular stent is predominant.

Cardiovascular stent: In 2013, the Chinese cardiovascular stent market equaled RMB11.2 billion, 78.8% of which was occupied by domestic drug-eluting stents. That same year, 686,000 units of cardiovascular stent were consumed in China, up 11.7% year on year, and drug-eluting stents accounted for 99.5%, indicating that the drug-eluting stent is gradually becoming an important device for interventional cardiovascular therapy.

In addition, Abbott has developed biodegradable stents, which are sold in Europe; Lepu Medical is endeavoring to develop biodegradable stents, which are expected to be available on the market in 2017. Thanks to its excellent performance, biodegradable stents are likely to replace drug-eluting stents gradually in the future, thus becoming the main variety in domestic coronary stent market.

Balloon catheter: In 2013, China’s demand for PTCA balloon catheter amounted to 1.186 million units, 500,000 of which were PTCA balloon catheters for dilatation. With rapid development of local PTCA balloon catheter producers represented by Lepu Medical, MicroPort and JW Medical, domestic PTCA balloon catheters increased its market share from 20% in 2009 to 40% in 2013.

Affected by the implementation of “Regulations on the Centralized Procurement of High-value Medical Consumables”, purchase price of interventional cardiovascular devices will continue to decline, further squeezing profit margins of relevant companies. However, the substantial decline in prices will enable more patients to receive PCI, thus helping the industry maintain a fairly rapid growth rate. It is expected that the Chinese interventional cardiovascular device market will worth RMB41.2 billion by 2017.

心血管介入器械 英文_副本.png

China Interventional Cardiovascular Device Industry Report, 2014-2017 focuses on the following:
20120114.gifStatus quo of China interventional cardiovascular device industry, including overview, market demand, import & export, competitive landscape and entry barriers;
20120114.gifDevelopment environment of China interventional cardiovascular device industry, embracing macro environment, policy climate and upstream & downstream sectors;
20120114.gifStatus quo, competitive landscape, etc. of China interventional cardiovascular device market segments, covering coronary stent, balloon catheter, catheter, guidewire, sheath group and auxiliary devices;
20120114.gifOperation, interventional cardiovascular device business, etc. of 6 foreign and 12 Chinese interventional cardiovascular device companies.

1. Overview of Interventional Cardiovascular Device Industry 
1.1 Definition
1.2 Classification and Application of Products 
1.3 Industry Chain

2. Status Quo of China Interventional Cardiovascular Device Industry
2.1 Overview
2.2 Market Demand
2.3 Import & Export
2.4 Competitive Landscape
2.5 Entry Barriers
2.5.1 Technology
2.5.2 Talent
2.5.3 Patent
2.5.4 Policy
2.5.5 Market Channel

3. Development Environment of China Interventional Cardiovascular Device Industry
3.1 Macro Environment
3.2 Policy Climate
3.2.1 Regulatory Policies
3.2.2 Industrial Policies
3.3 Upstream & Downstream Sectors
3.3.1 Upstream
3.3.2 Downstream

4. Market Segments of China Interventional Cardiovascular Device Industry
4.1 Coronary Stent
4.1.1 Market Profile
4.1.2 Drug-Eluting Stent
4.1.3 Bioabsorbable Stent
4.2 Balloon Catheter
4.2.1 Market Profile
4.2.2 Supply & Demand
4.3 Catheter
4.4 Guidewire
4.5 Sheath Group and Auxiliary Devices

5. Foreign Companies in China
5.1 Johnson & Johnson
5.1.1 Profile
5.1.2 Operation
5.1.3 Revenue Structure
5.1.4 Gross Margin
5.1.5 Interventional Cardiovascular Device Business
5.1.6 Development in China
5.2 Medtronic
5.2.1 Profile
5.2.2 Operation
5.2.3 Interventional Cardiovascular Device Business
5.2.4 Development in China
5.3 Boston Scientific
5.3.1 Profile
5.3.2 Operation
5.3.3 Interventional Cardiovascular Device Business
5.3.4 Development in China
5.4 Abbott Laboratories
5.4.1 Profile
5.4.2 Operation
5.4.3 Interventional Cardiovascular Device Business
5.4.4 Development in China
5.5 B. Braun
5.5.1 Profile
5.5.2 Operation
5.5.3 Interventional Cardiovascular Device Business
5.5.4 Development in China
5.6 Terumo
5.6.1 Profile
5.6.2 Operation
5.6.3 Interventional Cardiovascular Device Business
5.6.4 Development in China

6. Major Domestic Companies
6.1 MicroPort
6.1.1 Profile
6.1.2 Operation
6.1.3 Revenue Structure
6.1.4 Interventional Cardiovascular Device Business
6.1.5 R&D and Investment
6.1.6 Forecast and Outlook
6.2 Lepu Medical
6.2.1 Profile
6.2.2 Operation
6.2.3 Revenue Structure
6.2.4 Gross Margin
6.2.5 Interventional Cardiovascular Device Business
6.2.6 R&D and Investment
6.2.7 Forecast and Outlook
6.3 Lifetech Scientific
6.3.1 Profile
6.3.2 Operation
6.3.3 Revenue Structure
6.3.4 Interventional Cardiovascular Device Business
6.3.5 R&D and Investment
6.3.6 Forecast and Outlook
6.4 JW Medical
6.4.1 Profile
6.4.2 Interventional Cardiovascular Device Business
6.5 Dalian Yinyi
6.5.1 Profile
6.5.2 Interventional Cardiovascular Device Business
6.6 Neich Medical (Shenzhen)
6.6.1 Profile
6.6.2 Interventional Cardiovascular Device Business
6.7 SCW Medicath
6.7.1 Profile
6.7.2 Interventional Cardiovascular Device Business
6.8 Demax Medical
6.8.1 Profile
6.8.2 Interventional Cardiovascular Device Business
6.9 Starway Medical
6.9.1 Profile
6.9.2 Interventional Cardiovascular Device Business
6.10 Synexmed
6.10.1 Profile
6.10.2 Interventional Cardiovascular Device Business
6.11 Sino Medical
6.11.1 Profile
6.11.2 Interventional Cardiovascular Device Business
6.12 AmsinoMed Medical Device
6.12.1 Profile
6.12.2 Interventional Cardiovascular Device Business

7 Forecast and Outlook
7.1 Industry
7.2 Market Segments
7.2.1 Coronary Stent
7.2.2 Balloon Catheter
Types and Functions of Interventional Cardiovascular Device 
Types and Features of Cardiovascular Stent 
Interventional Cardiovascular Device Industry Chain in China
Total Industrial Output Value and YoY Growth of China Medical Device Industry, 2005-2013
Revenue and YoY Growth of China Medical Device Industry, 2005-2013
Market Size and YoY Growth of China Interventional Cardiovascular Device Industry, 2009-2013
Number of Patients with Cardiovascular Disease in China, 2013
Death Rate Percentage of Major Diseases in Rural Area, 2012
Death Rate Percentage of Major Diseases in Urban Area, 2012
Changes in Mortality Rate of Coronary Heart Disease in Urban and Rural Areas of China, 2002-2011
Number of PCI Cases and Growth Rate in China, 2011-2013
Coronary Stent Implantation and Usage Percentage of Drug-eluting Stent in China, 2011-2013
Import Share and Import Prices of Main Interventional Medical Devices in China, 2008
China’s Intravascular Stent Imports and Exports by Top 10 Countries, 2013
Market Structure of China Interventional Cardiovascular Device Industry, 2013
Number of Congenital Heart Disease Patients Receiving Interventional Therapy in China, 2012-2013
Business Models of China Interventional Cardiovascular Device Industry
China’s GDP and YoY Growth, 1985-2013
Main Policies Concerning Interventional Cardiovascular Device in China, 2006-2013
Number of Medical Institutions and Sickbeds in China, 2012-2013
Number of Hospitals in China (by Grade), 2010-Jun. 2014
Medical Service Quantity of Health Care Facilities in China, 2012-2013
Usage of Sickbeds in China’s Medical Institutions, 2012-2013
Health Costs and % of GDP in China, 1980-2013
Per Capita Health Costs and YoY Growth Rate in China, 2006-2013
Number of People 65 and Over and % of Total Population in China, 2004-2013
Ratio between Per Capita Income of Urban and Rural Households in China, 1980-2013
Medical Insurance Coverage and Expenditure in China
Proportion of Medical Insurance-covered Payment for Interventional Operation in Beijing, Shanghai and Guangzhou, 2011
Market Share of China-made Coronary Drug-eluting Stent System, 2009-2013
Market Share of Main Coronary Stent System Brands in China (by Consumption), 2013
Implantation of Coronary Stent in China, 2011-2013
China’s Coronary Stent Market Size and YoY Growth, 2012-2017E
Comparison of Relevant Data about PCI in China, 2011-2013
List of Main Domestic Drug-eluting Stent Products, 2013
Market Share of Imported and Domestic PTCA Balloon Catheter Products, 2013
China's Interventional Cardiovascular Balloon Catheter Market Size, 2012-2017E
China’s Demand for PTCA Balloon Catheter, 2011-2013
China's Interventional Cardiovascular Catheter Market Size, 2012-2017E
China's Interventional Cardiovascular Guide Wire Market Size, 2012-2017E
China's Interventional Cardiovascular Sheath Group and Auxiliary Device Market Size, 2012-2017E
Total Revenue and Net Income of Johnson & Johnson, 2009-2014
Total Revenue Breakdown of Johnson & Johnson (by Product), 2009-2014
Total Revenue Structure of Johnson & Johnson (by Product), 2009-2014
Gross Margin of Johnson & Johnson, 2009-2014
Johnson & Johnson’s Revenue from Cardiovascular Business and YoY Growth, 2009-2013
Johnson & Johnson’s Companies in China and Their Main Products
Revenue and Net Income of Medtronic, FY2009-FY2013
Revenue Breakdown of Medtronic (by Product), FY2009-FY2013
Revenue Structure of Medtronic (by Product), FY2009-FY2013
Medtronic’s Revenue from Coronary Artery Products and % of Total Revenue, FY2009-FY2013
Revenue, Net Income and Gross Margin of Boston Scientific, 2009-2013
Revenue Breakdown of Boston Scientific (by Division), 2009-2013
Revenue Breakdown of Boston Scientific (by Region), 2009-2013
Boston Scientific’s Revenue from Cardiovascular Division and YoY Growth, 2009-2013
Revenue, Net Income and Gross Margin of Abbott, 2009-2013
Revenue Breakdown of Abbott (by Product), 2009-2013
Revenue Structure of Abbott (by Product), 2009-2013
Revenue from Cardiovascular Products and % of Total Revenue, 2009-2013
Revenue, Net Income and Gross Margin of B. Braun, 2009-2013
Revenue Breakdown of B. Braun (by Division), 2009-2013
Revenue Breakdown of B. Braun (by Region), 2009-2013
Revenue and YoY Growth of B. Braun's Aesculap Division, 2009-2013
Revenue and Net Income of Terumo, FY2010-FY2013
Revenue of Terumo by Business, FY2010-FY2013
Revenue of Terumo by Region, FY2010-FY2013
R&D Cost and Proportion in Revenue of Terumo, FY2010-FY2013
Revenue from Cardiovascular Business and Revenue Share of Terumo, FY2010-FY2013
PTCA Balloon Dilatation Catheter Output and YoY Growth of Terumo, FY2009-FY2013
Angiographic Guidewire Output and YoY Growth of Terumo, FY2009-FY2013
PTCA Guidewire Output and YoY Growth of Terumo, FY2009-FY2013
China Branches and Their Business of Terumo
Terumo’s Layout in China
Revenue, Net Income and Gross Margin of MicroPort, 2009-2013
Revenue Breakdown of MicroPort (by Product), 2011-2013
Revenue Structure of MicroPort (by Product), 2011-2013
Revenue Breakdown of MicroPort (by Region), 2009-2013
Revenue Structure of MicroPort (by Region), 2009-2013
MicroPort’s Revenue from Interventional Cardiovascular Products and % of Total Revenue, 2011-2013
MicroPort’s Advantages in Heart Drug-eluting Stent Field
R&D Costs and % of Total Revenue of MicroPort, 2009-2013
Revenue and Net Income of MicroPort, 2012-2017E
Distribution of Lepu Medical’s Subsidiaries
Revenue, Net Income and Gross Margin of Lepu Medical, 2009-2013
Revenue Breakdown of Lepu Medical (by Product), 2009-2013
Revenue Breakdown of Lepu Medical (by Region), 2009-2013
Gross Margin of Lepu Medical (by Product), 2009-2013
R&D Costs and % of Total Revenue of Lepu Medical, 2010-2013
Lepu Medical’s Projects with Raised Funds and Progress
Revenue and Net Income of Lepu Medical, 2012-2017E
Revenue, Net Income and Gross Margin of Lifetech Scientific, 2009-2013
Revenue Breakdown of Lifetech Scientific (by Business), 2009-2013
Revenue Structure of Lifetech Scientific (by Business), 2009-2013
Lifetech Scientific’s Revenue from Congenital Heart Disease Business, YoY Growth and % of Total Revenue, 2009-2013
Lifetech Scientific’s Revenue from Peripheral Vascular Disease Business, YoY Growth and % of Total Revenue, 2009-2013
R&D Costs, YoY Growth and % of Total Revenue of Lifetech Scientific, 2010-2013
Revenue and Net Income of Lifetech Scientific, 2012-2017E
Balloon Compliance of JW Medical’s EXCEL Drug-eluting Stent Delivery System
Features of Dalian Yinyi’s Balloon Dilatation Catheters
Technical Parameters of COMBO Dual Therapy Stent
SCW Medicath’s PTCA Balloon Dilatation Catheters
Features and Advantages of SCW Medicath’s PTCA Balloon Dilatation Catheters
Technical Parameters of SCW Medicath’s PTCA Balloon Dilatation Catheters
Technical Parameters of Demax Medical’s Gusta? PTCA Balloon Dilatation Catheters
Technical Parameters of Demax Medical’s Gusta? PTCA Non-compliance Balloon Dilatation Catheters
Main Technical Parameters of Synexmed’s Advancer? PTCA Balloon Catheter
Main Technical Parameters of Synexmed’s Advancer Plus? PTCA/CTO Balloon Catheter
Main Technical Parameters of Synexmed’s Advancer Hp? High Pressure Balloon Catheter
Technical Parameters of Synexmed’s RUNNER? Coronary Stent
Technical Parameters of Synexmed’s CHALLENGER? Coronary Stent
Technical Parameters of Synexmed’s RAPA? Rapamycin Drug-eluting Coronary Stent
Technical Parameters of Sino Medical’s BuMA? Drug-eluting Stent
Technical Parameters of Sino Medical’s SUN Coronary Stent
Diagram for Balloon Passing External Diameter of Sino Medical’s Sleek PTCA Rapid Exchange Dilatation Balloon Catheter
Market Size and YoY Growth of China Interventional Cardiovascular Device Industry, 2012-2017E

China Blood Product Industry Report, 2020-2027

With the adjustment in the catalog of medicines covered by national medical insurance system, the scope and reimbursement ratio of almost all blood products for clinical use grow tremendously, which h...

China Medical Robot Industry Report, 2020-2026

Medical robot is the most promising segment of service robot market. By one estimate, globally 7,200 units of medical robots were sold and valued at $2.58 billion in 2019, compared with 5,100 units (u...

China In Vitro Diagnostic (IVD) Industry Report, 2019-2025

In vitro diagnosis (IVD) as a good way to make a rapid and definite diagnosis of diseases early, plays an increasingly crucial role in clinical medicine and related medical research fields. China’s IV...

China Aged Care Industry Report, 2019-2025

China’s society has aged before it gets rich. By the end of 2018, people aged over 60 had numbered 249.5 million in the country, or 17.9% of the total population, of which those aged over 65 were 167 ...

China Dental Industry Report, 2019-2025

Nowadays, the Chinese people have a growing awareness of oral health and healthy behaviors. 60.1% of residents have knowledge about oral health; 24.1% of 5-year-old children and 31.9% of 12-year-old c...

China Hospital Industry Report,2019-2025

The people’s growing awareness of health care and the acceleration of population aging have brought prosperity to China’s hospital industry. As of February 2019, there had been a total of 33,000 hospi...

China Dental Industry Report, 2017-2021

As living standards continue to improve and the awareness of oral health grows, consumers’ demand for dental services has kept increasing and the dental industry in China has witnessed robust developm...

China Interferon Industry Report, 2016-2021

Interferon is mainly used for the treatment of hepatitis B, hepatitis C, multiple sclerosis, condyloma acuminatum and other diseases. Wherein, IFN-α is mainly suitable for curing hepatitis B and hepat...

China Hospital Industry Report,2016-2020

In recent years, "Opinions on Promoting the Development of Health Service Industry" and other related policies, the people’s growing awareness of health care and the acceleration of population aging h...

China Aged Care Industry Report, 2016-2020

China entered the aging society early in 1999. By the end of 2015, China’s population aged over 60 reached 222 million and the old-age dependency ratio 13.9%. By 2020, China’s population aged over 60 ...

China Medical Robotics Industry Report, 2016-2020

Medical robotics can be used in surgery, rescue, transport, care, rehabilitation, dispensing and so on for the sick and wounded. Especially, surgical, rehabilitation and dispensing robots are the R &a...

China Dental Industry Report, 2016-2020

The dental industry refers to medical industrial chain on the basis of oral medical consumption, consisting mainly of dental apparatus (equipments and consumables), dental medical services, etc. With ...

China Medical Imaging Diagnosis Industry Report, 2015-2019

Against the background of a surge in social demand, handsome profit and the favorable opportunity brought by health care reform, the medical imaging industry, especially medical imaging equipment indu...

China Heparin Industry Report, 2015-2018

As the world's largest heparin API producer and exporter, China seizes about 80% share of the global heparin API market. After the explosive growth in 2008-2010, the stagnant international market and ...

Global and China Stem Cell Industry Report, 2015-2018

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Currently, stem cells are used to treat hund...

China Hospital Industry Report, 2015-2018

Stimulated by the demand, the number of hospitals in China rose from 21,979 in 2011 to 26,479 at the end of May 2015, an increase of 4,500 in total. Among them, public hospitals showed an overall decl...

China Independent Clinical Laboratory Industry Report, 2015-2018

The independent clinical laboratory originated from the U.S. and is relatively mature in developed countries/regions like North America, Europe, and Japan, whose independent clinical laboratory market...

China Medical Robot Industry Report, 2014-2018

Medical robots can be applied to surgeries, rescue, transport, nursing and rehabilitation of the sick and wounded. Wherein, surgery and rehabilitation robots are two striking market segments. Due to ...

2005- All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号